Operating cash flow has been negative in most periods, with 2026Q3 operating cash outflow of -$6.2M matching the net loss, and free cash flow remains persistently negative with no dividends and minimal buybacks suggesting capital is retained for trials.
Monopar Therapeutics Inc. (MNPR) cash flow statement — 11-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 |
|---|
| Cash from Operations | -3.26B | -12.2M | -6.4M | -7.86M | -7.23M | -7.32M | -4.66M | -3.02M | -2.89M | -2.63M | -1.19M | -636.33K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -225.34% | -90.52% | 18.5% | -8.71% | 1.21% | -56.95% | -54.5% | -4.54% | -9.87% | -119.94% | -87.74% | - |
| Net Income | -20.6M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.23M | -16.55M | -1.19M | -687.31K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 6.51M | 0 | 3.33M | 2.1M | 1.19M | 0 |
| Stock-Based Compensation | 1.43B | 4.84M | 1.14M | 1.9M | 1.64M | 1.47M | 1.32M | 1.01M | 529.33K | 305.2K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 848.98M | -716.46K | 4.54M | 0 | 0 | 0 | -6.63M | 0 | -3.33M | 11.4M | -1.19M | -73.84K |
| Working Capital Changes | -214.14M | -2.61M | 3.5M | -1.35M | 1.65M | 317.77K | 443.81K | 196.02K | -188.16K | 120.58K | -9.04K | 50.98K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.56B | 388.22K | 506.79K | -1.33M | 1.48M | 403.97K | 447.6K | 243.53K | 87.68K | 247.36K | -9.33K | 73.84K |
| Cash from Investing | 4.05B | -63.45M | -14.34M | 4.93M | -4.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -647.39M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M | 8.18M | 9.35M | -206.27K | 9.54M | 1.26M | 3.44M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 122.4K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 8.17M | 92.71M | 59.4M | 2.07M | 109.34K | 10.93M | 8.18M | 10.22M | 0 | 4.71M | 1.26M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -200.2K | -35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -655.56M | -1.13M | -104.14K | -46.97K | -76.46K | -45.77K | -115.57K | -874.81K | -206.27K | 4.83M | 0 | 3.44M |
| Net Change in Cash | 138.25M | 16.02M | 38.55M | -920.11K | -12.12M | 3.57M | 3.52M | 6.32M | -2.89M | 6.91M | 67.87K | 2.81M |
| Free Cash Flow | -3.26B | -12.2M | -6.4M | -7.86M | -7.23M | -7.32M | -4.66M | -3.02M | -2.89M | -2.63M | -1.19M | -636.33K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -30006.78% | -90.52% | 18.5% | -8.71% | 1.21% | -56.95% | -54.5% | -4.54% | -9.87% | -119.94% | -87.74% | - |
| FCF per Share | -380.83 | -1.65 | -0.56 | -0.54 | -0.57 | -0.59 | -0.43 | -0.29 | -0.28 | -0.25 | -0.12 | -0.08 |
| FCF Conversion (FCF/Net Income) | 158.25x | 0.89x | 0.41x | 0.94x | 0.69x | 0.80x | 0.74x | 0.71x | 0.89x | 0.16x | 1.01x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MNPR stock.
Monopar Therapeutics Inc. (MNPR) generated $-12.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Monopar Therapeutics Inc. (MNPR) reported negative free cash flow of $12.2M in 2025, indicating capital requirements exceeded cash from operations.
Monopar Therapeutics Inc. (MNPR) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Monopar Therapeutics Inc. (MNPR) spent $35.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Ongoing clinical cash burn without revenue
Metrics are mathematically derived from official filings.
Net Losses Mirror Operating Cash Burn
Based on reported quarterly figures, MNPR's operating cash flow has been negative in most periods, with 2026Q3 showing operating cash flow of -$6.2M that matches its net loss almost exactly, implying minimal accrual distortion in the reported losses.
Because operating cash flow tracks net income closely in several quarters, reported losses appear to be largely real cash outflows rather than non-cash charges. The OCF/NI ratio near 1.00 in 2026Q3 and 0.89 in 2026Q1 suggests the earnings base is cash-consistent, though the 2026Q2 figure appears anomalous and warrants further investigation before drawing conclusions. Investors should monitor whether this cash-consistent pattern persists as trial spending scales.
Free Cash Flow Remains Persistently Negative
As reported in the quarterly cash flow statements, MNPR's free cash flow has been negative across all ten periods, with the most recent quarter showing -$6.2M, indicating no internal funding capacity from operations.
With capital expenditures effectively zero, free cash flow equals operating cash flow, and the absence of any positive quarter reflects a business with no revenue offset. The magnitude of burn in 2026Q2, which the data flags at an unusually large figure, appears inconsistent with surrounding quarters and may reflect a reporting or classification issue that warrants further investigation. The overall trajectory suggests reliance on external capital to sustain operations.
Cash Directed to Trials, Not Shareholders
Based on reported figures, MNPR paid no dividends in any period and recorded buybacks only in 2026Q1 at -$200.2K, with no acquisition cash flows reported, suggesting capital is being retained for clinical programs.
The absence of dividends and the negligible buyback activity are consistent with a company that must preserve liquidity to fund Validive and Camsirubicin development. The single 2025Q3 outflow near -$35.0M is not clearly explained by the supplied data and should not be read as a sustainable deployment pattern. Shareholders should recognize that any return of capital is unlikely while the company remains pre-revenue.
Working Capital Swings Obscure Burn Rate
According to the reported cash flow data, MNPR's working capital changes swung from -$213.8M in 2026Q2 to +$1.4M in 2025Q4, with figures of this magnitude appearing inconsistent with the company's scale and suggesting data-quality limitations.
Large swings in working capital can distort the apparent operating burn, and the extreme 2026Q2 figure makes the quarterly trend difficult to interpret reliably. Accrued clinical trial expenses, which the company typically carries, may lag actual activity and contribute to these fluctuations. Analysts should rely on cumulative operating burn rather than any single quarter's working capital reading.
Burn Rate Obscured by Data Anomalies
Based on the supplied cash flow series, the most reliable read of MNPR's burn comes from the smaller quarterly outflows, since anomalous 2026Q2 and 2025Q3 entries could materially overstate or understate the true cash consumption rate.
Taken at face value, the extreme values in the reported working capital and operating cash flow lines would imply a very different funding picture than the modest net losses on the income statement, which warrants further investigation rather than acceptance. Stock-based compensation add-backs of up to $2.0M per quarter reduce the reported cash gap without changing the underlying need for external capital. Investors should treat the cumulative burn trend and the cash runway implied by the balance sheet as more decision-useful than any isolated quarter.